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for its calculation. Methods: A PubMed search was performed using the key-
words: child/pediatrics, immunization, administration and direct service costs/
costs and cost analysis/economics/health care costs/cost/fees, medical/cost 
benefit analysis, limited to publications in English, for infants up to 23 months, 
from 2004 onwards. Publications not referring to pediatric vaccination, not stating 
vaccine administration cost alone, and review studies were excluded. Results: 
Fourteen out of 167 articles were included in the analysis. Eight (57%) studies 
were conducted in the US, two in the UK, and four in low/middle income coun-
tries. Vaccine administration settings were public/private combined (42%), public 
only (29%) and private only (29%). Six studies (43%) looked into any vaccination 
type, followed by Rotavirus (14%), and influenza vaccines (14%); all other vaccines 
29%. Ten studies (72%) used secondary data sources. Two studies employed pro-
spective primary data collection [Time and Motion (T&M) methodology, survey/
diary] and two studies used primary and secondary data combined. Four studies 
(29%) employed a top-down costing approach, two studies a bottom-up approach, 
and three studies a mixed method (no information for 5 studies). For half of the 
studies the cost calculation methodology was not clear. Administration cost per 
dose ranged from $0.4-$4.5 for low/middle income countries and from $5.2-$61 
for high income countries. Nine (64%) studies used vaccine administration cost 
as input into a pharmacoeconomic model, and six (36%) generated stand-alone 
results. ConClusions: Pediatric vaccine administration cost varies widely. 
Comparison of study results is difficult due to different country management 
practices, different costing structures, and different costing years. The cost was 
mainly calculated using secondary data. Only a few studies collected primary data. 
To generate more precise cost estimates, real-world evidence studies employing 
appropriate costing methodologies are warranted.
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objeCtives: Determine the cost to the Mexican health system, associated with the 
treatment of cervical cancer from 2004 to 2011 and to determine the cost associated 
with diagnosis and treatment of anogenital warts in the same period. Methods: 
Data from the databases of the general direction of health information and the 
epidemiological surveillance system (SUIVE) were analyzed to determine the inci-
dence reported by the government of cervical dysplasia, cervical cancer in situ 
and anogenital warts. Treatment costs were obtained according to DRG for cervical 
dysplasia and cervical cancer. For anogenital warts the cost was estimated accord-
ing to data obtained through a Delphi panel made in 2013 (accepted for publica-
tion in the Mexican Urology Journal Ref. UROMX-D-15-00004). Results: In the 
analyzed period of eight years, it was observed that there has been a decrease in 
spending in the treatment of cervical lesions by severe dysplasia or cancer in situ 
from 6,649,760,194 to 4,423,742,35 USD. Also the treatment of mild and moderate 
dysplasia has shown a decrease in spending from 22,798,807,215 to 21,507,746,764 
USD. In the other way, an increase in spending is observed when treating ano-
genital warts, this goes from 410,728,813 to 573,330,965 USD. ConClusions: The 
observed results are interesting to mention, since the decrease in the expense of 
treating cervical dysplasia may reflect greater Epidemiological surveillance and 
early diagnosis. But, is interestingly the increase in spending anogenital warts 
treatment, which can also be a result of increased diagnosis and awareness by 
health professionals. In México vaccination campaign against human papilloma 
virus began in 2007, we can’t currently assume a relationship between the cost 
of treating injuries and human papillomavirus vaccination, but is of great inter-
est to continue the observation of the impact that could have this public health 
intervention in the Mexican population, as well as the budgetary impact for 
México.
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objeCtives: Uterine fibroids (UF) are the most common benign gynecological 
tumors. Prevalence data range from 5% to 21% of adult women in reproductive age. 
Despite the progress in the development of modern effective drugs the primary 
treatment is still surgical interventions. At the same time, the trend in recent 
years of the increasing of the incidence of UF in younger women, expansion of 
childbearing age limits period necessitates the revision of management of UF. 
The aim of the study was to calculate the average cost of hormonal therapy of 
UF in Ukraine for a minimum period of 3 months, considering that the main 
aim of this therapy is to manage bleeding and pain symptoms and to provide 
pre-operative treatment of UF. Methods: We analyzed the cost of treatment 
hormones per patient for course. We used the real data from medical records 
of patients who were treated in the Lviv Regional Perinatal Center and Lviv 
Regional Clinical Hospital in 2014. We have analyzed almost 300 stories diseases 
for 2014. We used the prices from Ukrainian database of Morion company (Kiev) 
on 01.01.2015 (1 USD = 15,75 UAH). Results: In Ukraine for the treatment of UF 
often are used these treatment hormonal schemes. We calculated the costs for 
course per patient in 3 months duration. The treatment costs are: mifepristone 
(tab.50 mg №30) – $184 (◽2895); goserelin acetate (implant 3,6 mg) – $419 (◽6600)/
triptorelin (powder for susp. for injection 3,75 mg) – $571 (◽9000); ulipristal acetate 
(tab. 5 mg №28) – $595 (◽9375). ConClusions: Hormonal schemes of treatment 
are quite expensive for Ukrainian woman. In particular, the scheme of ulipristal 
is three times more expensive than the scheme with mifepristone. Almost all 
patients fully pay costs out-of-pocket. So implementation of health insurance 
and reimbursement policies of hormonal medicines is actual and on time in 
Ukraine.
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objeCtives: The aim of the study was to investigate the cost-effectiveness of 
13-valent pneumococcal conjugate vaccine (PCV-13) programme for children in 
Kazakhstan from the perspective of Ministry of Health. Methods: A Markov 
model was constructed to estimate the effects and directs costs of PCV-13 pro-
gramme compared to other PCV programmes for newborns initiated in Kazakhstan. 
Treatment efficacy and transition probabilities were synthesized from local regis-
tries of vaccination with 5 year follow-up. The characteristics of patient cohort and 
treatment costs (vaccine cost, monitoring, adverse effects management) in year 2014 
Kazakhstani tenge (KZT) were estimated from republican official sources. Annual 
3% discounting rate and 1 year cycles (with half-cycle corrections) were utilized 
for the model. Robustness of the model parameters was explored by one-way and 
probabilistic sensitivity analysis. Results: Analysis of the registries showed sig-
nificant decrease of incidence of diseases assosiated with S. pneumoniae in children 
that received the PCV-13. Moreover, the introduction of PCV-13 decreased the under 
1-age mortality due to pneumonia by half (95%CI, p value= 0.001). As a result of 5 
year stimulation of the model, the CER of PCV-13 was estimated as 8432 tenge/LYG 
or 8574 tenge/QALY, whereas CER for no PCV-13 was estimated as 7441 tenge/LYG 
or 7605 tenge/QALY. ICER was estimated as 122 070 tenge/QALY, which is within 
the cost-effectiveness threshold values recommended by WHO. ConClusions: 
The introduction of PCV-13 seems to be a cost-effective programme in Kazakhstan. 
These findings may better inform decision makers regarding formulary inclusion 
and reimbursement in the vaccine programmes in Kazakhstan.
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objeCtives: Mandatory employer-based insurance coverage of contraception in 
the U.S. has been a controversial component of the Affordable Care Act (ACA). Prior 
research has examined the cost-effectiveness of contraception in general; however, 
no studies have developed a formal decision-model in the context of the new ACA 
provisions. As such, this study aims to estimate the relative cost-effectiveness of 
contraception from the employer and societal perspectives, taking into considera-
tion newer regulations allowing for religious exemptions. Methods: A decision-
tree was developed from the employer and societal perspectives to simulate costs 
and outcomes associated with all contraceptive methods covered by the ACA. 
Method-specific estimates of contraception access, utilization, adherence, failure 
rates, outcomes, and costs were derived from the literature. Employer coverage rates 
and covariates (age, income, marital status, and access) were varied through sensi-
tivity analysis. Results: Compared to full coverage of contraception, providing no 
coverage resulted in 4.9 more pregnancies per 100 women of childbearing age. This 
subsequently increased the number of live births (3.6 per 100) and terminations (1.3 
per 100). Providing no coverage for contraception also resulted in greater societal 
healthcare costs owing to this increase in pregnancies. Coverage via a health sav-
ings account (HSA) resulted in a lower number of pregnancies and reduced costs 
due to the greater access to prescribing pharmacies. ConClusions: Although lack 
of coverage reduced drug costs, it ultimately resulted in a greater number of unin-
tended pregnancies. Whether the objection for coverage is due to costs or increasing 
terminations, denying full coverage of contraceptives appears to have the opposite 
consequence of increasing total costs as well as the total number of terminations. 
Coverage of contraceptives via an HSA may provide a compromise.
